| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.2M | — | -45.4% |
| SG&A Expense | $1.3M | — | +10.5% |
| Operating Income | -$2.5M | — | +25.6% |
| Net Income | -$2.4M | — | +27.3% |
| EPS (Basic) | -$0.96 | — | -336.4% |
| EPS (Diluted) | -$0.96 | — | -336.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $10.2M | -14.1% | +1002.8% |
| Current Assets | $10.9M | -14.2% | +560.6% |
| Total Assets | $12.3M | -12.8% | +301.0% |
| Current Liabilities | $2.2M | +4.5% | -14.7% |
| Total Liabilities | $2.3M | +3.9% | -15.3% |
| Stockholders' Equity | $10.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.8M | — | +8.2% |
| Financing Cash Flow | $150K | — | -54.3% |
| +2887.7% |